| 研究課題/領域番号 |
21K18062
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分90110:生体医工学関連
|
|---|
| 研究機関 | 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター) |
|---|
研究代表者 |
ディリサラ アンジャネユル 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 研究員 (70794353)
|
|---|
| 研究期間 (年度) |
2021-04-01 – 2023-03-31
|
| 研究課題ステータス |
交付 (2021年度)
|
| 配分額 *注記 |
4,550千円 (直接経費: 3,500千円、間接経費: 1,050千円)
2022年度: 2,210千円 (直接経費: 1,700千円、間接経費: 510千円)
2021年度: 2,340千円 (直接経費: 1,800千円、間接経費: 540千円)
|
|---|
| キーワード | Liver stealth coating / Hepatocyte targeting / Gene delivery / Hepatocytes / Genome editing / CRISPR/Cas9 / Gene drugs |
|---|
| 研究開始時の研究の概要 |
Hepatocyte-selective delivery of nanomedicines is a potential strategy for treating liver diseases. However, liver scavenger cells eliminate most of the injected dose before reaching hepatocytes. Research will be focused on minimizing this nonspecific uptake to maximize hepatocyte-directed delivery.
|
| 研究実績の概要 |
The luciferase-encoding mRNA encapsulated cationic (lipid to mRNA ratio 5:1, charge +52 mV, size 155 nm) and anionic (lipid to mRNA ratio 1:2, charge -30 mV, size 221 nm) mRNA-lipoplexes were prepared by different coating amounts of the mRNA onto liposomes composed of DOTMA and DOPE. Prior stealth coating of the liver sinusoidal RES wall with two-arm-PEG-Oligo(L-Lysine) substantially enhanced the luciferase expression (14.1-fold increase) of anionic liposome in the liver compared to without liver coating. Similarly, PEG coating to the liver scavenger cell wall augmented the luciferase expression in the liver up to 3.6-fold compared to without coating. Based on these results, the applicant will choose anionic mRNA-lipoplex for future liver-directed therapeutic applications.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
We have optimized the best-in-class mRNA-lipoplex carrier for mRNA introduction into the liver using the mRNA-encoding reporter protein, luciferase, using a bioluminescence assay.
|
| 今後の研究の推進方策 |
Rather than developing new carriers for mRNA delivery, the applicant will focus on relocating the existed mRNA carriers from the liver scavenger cells, liver sinusoidal endothelial cells, and Kupffer cells to the parenchymal hepatocytes without integrating complicated structural functionalities such as introducing surface ligands, charge and size modulation. In the future, such hepatocyte-selective protein expression will be exploited to develop a cure for chronic hepatitis B by destroying the virus's persistent covalently closed circular (ccc)DNA using a gene-editing tool, clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated protein 9.
|
